

Ondřej Kubeček

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8189041/publications.pdf>

Version: 2024-02-01

19
papers

308
citations

1163117

8
h-index

888059

17
g-index

24
all docs

24
docs citations

24
times ranked

532
citing authors

#	ARTICLE	IF	CITATIONS
1	The pathogenesis, diagnosis, and management of metastatic tumors to the ovary: a comprehensive review. <i>Clinical and Experimental Metastasis</i> , 2017, 34, 295-307.	3.3	99
2	Nivolumab induced encephalopathy in a man with metastatic renal cell cancer: a case report. <i>Journal of Medical Case Reports</i> , 2018, 12, 262.	0.8	44
3	Distant Metastasis in Colorectal Cancer Patients—Do We Have New Predicting Clinicopathological and Molecular Biomarkers? A Comprehensive Review. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5255.	4.1	38
4	Treatment possibilities of ipilimumab-induced thrombocytopenia—case study and literature review. <i>Japanese Journal of Clinical Oncology</i> , 2015, 45, 381-384.	1.3	28
5	Microsatellite instability in melanoma: a comprehensive review. <i>Melanoma Research</i> , 2016, 26, 545-550.	1.2	26
6	Hepatic Injury Induced by a Single Dose of Nivolumab — a Case Report and Literature Review. <i>Klinicka Onkologie</i> , 2019, 32, 133-138.	0.3	17
7	Microsatellite instability as a predictive factor for immunotherapy in malignant melanoma. <i>Medical Hypotheses</i> , 2016, 93, 74-76.	1.5	14
8	Dermatomyositis with anti-TIF-1 ^β antibodies as a presenting symptom of underlying triple-negative breast cancer: a case report. <i>BMC Cancer</i> , 2016, 16, 684.	2.6	12
9	Plasmafiltration as a possible contributor to kinetic targeting of pegylated liposomal doxorubicin (PLD) in order to prevent organ toxicity and immunosuppression. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 77, 429-437.	2.3	6
10	Risk Factors for Infections, Antibiotic Therapy, and Its Impact on Cancer Therapy Outcomes for Patients with Solid Tumors. <i>Life</i> , 2021, 11, 1387.	2.4	6
11	Plasmafiltration as an effective method in the removal of circulating pegylated liposomal doxorubicin (PLD) and the reduction of mucocutaneous toxicity during the treatment of advanced platinum-resistant ovarian cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 85, 353-365.	2.3	4
12	Therapeutic Apheresis, Circulating PLD, and Mucocutaneous Toxicity: Our Clinical Experience through Four Years. <i>Pharmaceutics</i> , 2020, 12, 940.	4.5	3
13	Prognostic value of blood cell count-derived ratios in BRAF-mutated metastatic melanoma. <i>Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia</i> , 2022, 166, 393-404.	0.6	2
14	Extracorporeal apheresis system - A nanoparticle drugs' elimination method to enhance the benefit of cytostatic therapy in cancer patients. <i>Journal of Applied Biomedicine</i> , 2016, 14, 91-96.	1.7	1
15	Administration of Nivolumab in Metastatic Renal Cell Cancer Following Treatment With mTOR Inhibitors. <i>In Vivo</i> , 2021, 35, 2981-2990.	1.3	1
16	Clinicopathological Characteristics and Prognostic Factors in Ovarian Metastases from Right- and Left-Sided Colorectal Cancer. <i>Current Oncology</i> , 2021, 28, 2914-2927.	2.2	1
17	Extracorporeal Elimination of Circulating Pegylated Liposomal Doxorubicin (PLD) to Enhance the Benefit of Cytostatic Therapy in Platinum-Resistant Ovarian Cancer Patients. <i>Acta Medica (Hradec) Tj ETQq1 1 0.784314 rgBI /Overlook</i>	1.3	1
18	Combined Therapy of Locally Advanced Oesophageal and Gastro—Oesophageal Junction Adenocarcinomas: State of the Art and Aspects of Predictive Factors. <i>Cancers</i> , 2021, 13, 4591.	3.7	0

#	ARTICLE	IF	CITATIONS
19	How to manage side effects of immunotherapy. Onkologie (Czech Republic), 2020, 14, 6-12.	0.1	0